Takeda Oncology Development Pipeline

First Page		Document Content
Date: 2016-05-06 15:30:27 Seattle Genetics Monoclonal antibodies Brentuximab vedotin Oncology Protein kinase inhibitor Proteasome inhibitor Antineoplastic drugs Cancer Proteasome Tumors of the hematopoietic and lymphoid tissues Targeted therapy Phosphoinositide 3-kinase inhibitor		Takeda Oncology Development Pipeline Add to Reading List Source URL: www.takedaoncology.com Download Document from Source Website File Size: 211,15 KB Share Document on Facebook

	Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro DocID: 1v2t4 - View Document
	Journal of Cellular Biochemistry 103:972–Raf Kinase Inhibitor Protein Positively Regulates Cell–Substratum Adhesion While Negatively Regulating Cell–Cell Adhesion Kevin T. Mc Henry,1 Roberto Montesano,2 DocID: 1uOLU - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1r4cq - View Document
	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for DocID: 1pQS7 - View Document